Skip to main content
Top
Published in: Clinical Rheumatology 1/2007

01-01-2007 | Case Report

A case of mixed connective tissue disease complicated with thrombotic thrombocytopenic purpura

Authors: Takeshi Kuroda, Kouki Matsuyama, Takeshi Nakatsue, Syuuichi Murakami, Hisashi Hasegawa, Hideaki Nakayama, Minoru Sakatsume, Mitsuhiro Ueno, Masaaki Nakano, Fumitake Gejyo

Published in: Clinical Rheumatology | Issue 1/2007

Login to get access

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare complication of mixed connective tissue disease (MCTD). In this report, we describe the case of a 73-year-old Japanese woman with MCTD who developed fever, thrombocytopenia, and microangiopathic hemolytic anemia and was diagnosed with MCTD together with TTP. The activity of von Willebrand factor (vWF) cleaving metalloprotease ADAMTS13 was low and considered to have contributed to the disease activity of TTP. The patient died despite intensive treatment of plasma exchange (PEX) and steroid pulse therapy. Autopsy results revealed that the kidneys had platelet and fibrin thrombi, which occluded capillaries and arterioles. These findings were compatible with TTP and the decreased activity of ADAMTS13 was considered to be associated with the disease activity of TTP.
Literature
1.
go back to reference Parker Levine S (1999) Thrombotic thrombocytopenic purpura and other forms of non-immunologic platelet destruction. In: Lee GR (ed) Wintrobe’s clinical hematology, 10th edn. vol 2. Williams &Wilkins, Baltimore, pp1612–1622 Parker Levine S (1999) Thrombotic thrombocytopenic purpura and other forms of non-immunologic platelet destruction. In: Lee GR (ed) Wintrobe’s clinical hematology, 10th edn. vol 2. Williams &Wilkins, Baltimore, pp1612–1622
2.
go back to reference Paice EW, Snaith ML (1984) Thrombotic thrombocytopenic purpura occurring in a patient with mixed connective tissue disease. Rheumatol Int 43:141–142CrossRef Paice EW, Snaith ML (1984) Thrombotic thrombocytopenic purpura occurring in a patient with mixed connective tissue disease. Rheumatol Int 43:141–142CrossRef
3.
go back to reference ter Borg EJ, Houtman PM, Kallenberg CG, van Leeuwen MA, van Ryswyk MH (1988) Thrombocytopenia and hemolytic anemia in a patient with mixed connective tissue disease due to thrombotic thrombocytopenic purpura. J Rheumatol 15:1174–1177PubMed ter Borg EJ, Houtman PM, Kallenberg CG, van Leeuwen MA, van Ryswyk MH (1988) Thrombocytopenia and hemolytic anemia in a patient with mixed connective tissue disease due to thrombotic thrombocytopenic purpura. J Rheumatol 15:1174–1177PubMed
4.
go back to reference Poullin P, Lefevre P, Durand JM (1999) Mixed connective tissue disease with hemolytic anemia and severe thrombocytopenia due to thrombotic thrombocytopenic purpura. Am J Hematol 61:275CrossRefPubMed Poullin P, Lefevre P, Durand JM (1999) Mixed connective tissue disease with hemolytic anemia and severe thrombocytopenia due to thrombotic thrombocytopenic purpura. Am J Hematol 61:275CrossRefPubMed
5.
go back to reference Kato A, Suzuki Y, Fujigaki Y, Yamamoto T, Yonemura K, Miyajima H et al (2002) Thrombotic thrombocytopenic purpura associated with mixed connective tissue disease. Rheumatol Int 22:122–125CrossRefPubMed Kato A, Suzuki Y, Fujigaki Y, Yamamoto T, Yonemura K, Miyajima H et al (2002) Thrombotic thrombocytopenic purpura associated with mixed connective tissue disease. Rheumatol Int 22:122–125CrossRefPubMed
6.
go back to reference Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584CrossRefPubMed Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584CrossRefPubMed
7.
go back to reference Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594CrossRefPubMed Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594CrossRefPubMed
8.
go back to reference Tsai HM, Rice L, Sarode R, Chow TW, Moake JL (2000) Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 132:794–799PubMed Tsai HM, Rice L, Sarode R, Chow TW, Moake JL (2000) Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 132:794–799PubMed
9.
go back to reference Kasukawa R, Tojo T, Miyawaki S, Yoshida H, Tanimoto K, Nobunaga M et al (1987) Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds) Mixed connective tissue diseases and anti-nuclear antibodies, Elsevier, Amsterdam, pp41–47 Kasukawa R, Tojo T, Miyawaki S, Yoshida H, Tanimoto K, Nobunaga M et al (1987) Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds) Mixed connective tissue diseases and anti-nuclear antibodies, Elsevier, Amsterdam, pp41–47
10.
go back to reference Jain R, Chartash E, Susin M, Furie R (1994) Systemic lupus erythematosus complicated by thrombotic microangiopathy. Semin Arthritis Rheum 24:173–182CrossRefPubMed Jain R, Chartash E, Susin M, Furie R (1994) Systemic lupus erythematosus complicated by thrombotic microangiopathy. Semin Arthritis Rheum 24:173–182CrossRefPubMed
11.
go back to reference Kfoury Baz EM, Mahfouz RA, Masri AF (1999) Thrombotic thrombocytopenic purpura in a patient with rheumatoid arthritis treated by plasmapheresis. Ther Apher 3:314–316CrossRefPubMed Kfoury Baz EM, Mahfouz RA, Masri AF (1999) Thrombotic thrombocytopenic purpura in a patient with rheumatoid arthritis treated by plasmapheresis. Ther Apher 3:314–316CrossRefPubMed
12.
go back to reference Miller A, Ryan PF, Dowling JP (1997) Vasculitis and thrombotic thrombocytopenic purpura in a patient with limited scleroderma. J Rheumatol 24:598–600PubMed Miller A, Ryan PF, Dowling JP (1997) Vasculitis and thrombotic thrombocytopenic purpura in a patient with limited scleroderma. J Rheumatol 24:598–600PubMed
13.
go back to reference Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K (2001) Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059–41063CrossRefPubMed Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K (2001) Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059–41063CrossRefPubMed
15.
go back to reference Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494CrossRefPubMed Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494CrossRefPubMed
16.
go back to reference Veyradier A, Obert B, Houllier A, Meyer D, Girma JP (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98:1765–1772CrossRefPubMed Veyradier A, Obert B, Houllier A, Meyer D, Girma JP (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98:1765–1772CrossRefPubMed
17.
go back to reference Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V et al (2002) Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 71:105–108CrossRefPubMed Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V et al (2002) Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 71:105–108CrossRefPubMed
18.
go back to reference Remuzzi G, Ruggenenti P, Bertani T (1994) Thrombotic microangiopathy. In: Tisher CC, Brenner BM (eds) Renal pathology with clinical and functional correlations, 2nd edn. Lippincott, Philadelphia, pp1154–1186 Remuzzi G, Ruggenenti P, Bertani T (1994) Thrombotic microangiopathy. In: Tisher CC, Brenner BM (eds) Renal pathology with clinical and functional correlations, 2nd edn. Lippincott, Philadelphia, pp1154–1186
19.
go back to reference Kapur A, Ballou SP, Renston JP, Luna E, Chung-Park M (1997) Recurrent acute scleroderma renal crisis complicated by thrombotic thrombocytopenic purpura. J Rheumatol 24:2469–2472PubMed Kapur A, Ballou SP, Renston JP, Luna E, Chung-Park M (1997) Recurrent acute scleroderma renal crisis complicated by thrombotic thrombocytopenic purpura. J Rheumatol 24:2469–2472PubMed
Metadata
Title
A case of mixed connective tissue disease complicated with thrombotic thrombocytopenic purpura
Authors
Takeshi Kuroda
Kouki Matsuyama
Takeshi Nakatsue
Syuuichi Murakami
Hisashi Hasegawa
Hideaki Nakayama
Minoru Sakatsume
Mitsuhiro Ueno
Masaaki Nakano
Fumitake Gejyo
Publication date
01-01-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0105-1

Other articles of this Issue 1/2007

Clinical Rheumatology 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.